Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors
- PMID: 18782902
- PMCID: PMC2571066
- DOI: 10.2337/dc08-1013
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors
Abstract
Objective: The purpose of this study was to assess incidence of and risk factors for recurrent cardiovascular disease (CVD) in type 2 diabetes.
Research design and methods: We estimated the incidence of recurrent cardiovascular events in type 2 diabetic patients, aged 40-97 years, followed by a network of diabetes clinics. The analysis was conducted separately for 2,788 patients with CVD at enrollment (cohort A) and for 844 patients developing the first episode during the observation period (cohort B).
Results: During 4 years of follow-up, in cohort A the age-adjusted incidence of a recurrent event (per 1,000 person-years) was 72.7 (95% CI 58.3-87.1) in men and 32.5 (21.2-43.7) in women, whereas in cohort B it was 40.1 (17.4-62.9) in men and 22.4 (12.9-32.0) in women. After controls were included for potential predictors (familial CVD, obesity, smoking, diabetes duration, glycemic control, microvascular complications, geographic area, and antihypertensive and lipid-lowering treatment), male sex, older age, and insulin use were significant independent risk predictors (cohort A) and serum triglyceride levels >/=1.69 mmol/l emerged as the only metabolic (negative) prognostic factor (cohort B). In both cohorts, a prior CVD episode, especially myocardial infarction, was by far the strongest predictor of recurrent CVD.
Conclusions: Approximately 6% of unselected diabetic patients in secondary prevention develop recurrent major CVD every year. Those with long-standing previous CVD show a higher incidence of recurrence. Male sex, age, high triglyceride levels, and insulin use are additional predictors of recurrence.
Similar articles
-
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.Eur Heart J. 2019 Sep 7;40(34):2899-2906. doi: 10.1093/eurheartj/ehy839. Eur Heart J. 2019. PMID: 30629157 Free PMC article.
-
Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes.PLoS One. 2016 Oct 14;11(10):e0164807. doi: 10.1371/journal.pone.0164807. eCollection 2016. PLoS One. 2016. PMID: 27741306 Free PMC article.
-
Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014.BMC Public Health. 2017 Nov 22;17(1):893. doi: 10.1186/s12889-017-4921-4. BMC Public Health. 2017. PMID: 29166886 Free PMC article.
-
Incidence and predictors for cardiovascular disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study.J Diabetes Complications. 2016 Apr;30(3):444-50. doi: 10.1016/j.jdiacomp.2015.12.010. Epub 2015 Dec 17. J Diabetes Complications. 2016. PMID: 26774791
-
[Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required?].Med Clin (Barc). 2013 Sep;141 Suppl 2:7-13. doi: 10.1016/S0025-7753(13)70057-5. Med Clin (Barc). 2013. PMID: 24444518 Review. Spanish.
Cited by
-
Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure.Hypertension. 2011 May;57(5):891-7. doi: 10.1161/HYPERTENSIONAHA.110.162446. Epub 2011 Mar 14. Hypertension. 2011. PMID: 21403089 Free PMC article.
-
Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study.Diabetes Care. 2013 Nov;36(11):3498-502. doi: 10.2337/dc12-2691. Epub 2013 Jul 22. Diabetes Care. 2013. PMID: 23877981 Free PMC article.
-
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778. Circulation. 2019. PMID: 30586757 Free PMC article. Clinical Trial.
-
Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study.Diabetes Care. 2020 Apr;43(4):867-874. doi: 10.2337/dc19-2292. Epub 2020 Jan 30. Diabetes Care. 2020. PMID: 32001614 Free PMC article. Clinical Trial.
-
Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes.JAMA Netw Open. 2024 Oct 1;7(10):e2441765. doi: 10.1001/jamanetworkopen.2024.41765. JAMA Netw Open. 2024. PMID: 39476235 Free PMC article.
References
-
- Abbott RD, Donahue RP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. JAMA 260:3456–3460, 1988 - PubMed
-
- Miettinen H, Lehto S, Salomaa VV, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilheto J: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69–75, 1998 - PubMed
-
- Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality form coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998 - PubMed
-
- Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49:1772–1780, 2007 - PubMed
-
- The DAI Study Group: Prevalence of coronary heart disease in a cohort of type 2 diabetic patients in Italy: the DAI study. Diabet Med 21:738–745, 2004 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical